Our molecular analysis identified that the lead new quinazoline, DZ-50, disrupts tight junction formation in human prostate cancer cells by downregulating Claudin-11, a critical TJ protein, also contributing to the actin cytoskeleton [36], [37]. Here, CLDN11 is linked to prostate carcinoma.